Dr Jason Twohig

2023

• Rubina, A. et al. 2023. ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways. Proceedings of the National Academy of Sciences 120 (33) e2303155120. (10.1073/pnas.2303155120)

2020

• Cuff, S. M. et al. 2020. Toll-like receptor linked cytokine profiles in cerebrospinal fluid discriminate neurological infection from sterile inflammation. Brain Communications 2 (2) fcaa218. (10.1093/braincomms/fcaa218)

2019

• Twohig, J. P. et al. 2019. Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. Nature Immunology 20 , pp.458-470. (10.1038/s41590-019-0350-0)

2017

• Singh, R. et al. 2017. Death receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation. Cellular Immunology 320 , pp.62-70. (10.1016/j.cellimm.2017.09.005)

2016

• Perks, W. V. et al. 2016. Death Receptor 3 promotes chemokine directed leukocyte recruitment in acute resolving inflammation and is essential for pathological development of mesothelial fibrosis in chronic disease. American Journal of Pathology 186 (11), pp.2813-2823. (10.1016/j.ajpath.2016.07.021)

2014

• Wang, E. C. Y. et al. 2014. Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis and Rheumatology 66 (10), pp.2762-2772. (10.1002/art.38770)

2012

• Al-Lamki, R. S. et al., 2012. DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor. American Journal of Pathology 180 (4), pp.1454-1464. (10.1016/j.ajpath.2012.01.003)
• Twohig, J. P. et al. 2012. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. The FASEB Journal 26 (8), pp.3575-3586. (10.1096/fj.11-200618)

2011

• Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25 (1), pp.409-419. (10.1096/fj.10-166843)
• Wang, E. C. Y. et al. 2011. Control of early cartilage destruction in inflammatory arthritis by death receptor 3 [Abstract]. Immunology 135 (s1), pp.153-153. (10.1111/j.1365-2567.2011.03534.x)

2010

• Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131 (s1), pp.102-102. (10.1111/j.1365-2567.2010.03390.x)
• Twohig, J. P. et al. 2010. Age-dependent maintenance of motor controland corticostriatal innervation by death receptor 3. Journal of Neuroscience 30 (10), pp.3782-3792. (10.1523/JNEUROSCI.1928-09.2010)

2009

• Twohig, J. P. et al. 2009. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Molecular Immunology 46 (10), pp.2002-2013. (10.1016/j.molimm.2009.03.007)
• Williams, A. S. et al. 2009. A functional role for death receptor-3 in arthritis [Abstract]. Cytokine 48 (1-2), pp.134-134. (10.1016/j.cyto.2009.07.568)
• Williams, A. S. et al. 2009. Functional role of dr3 in inflammatory arthritis: A novel target for therapy? [Abstract]. Rheumatology 48 (s1), pp.I8-I8. (10.1093/rheumatology/kep704)

2008

• Bull, M. J. et al. 2008. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. Journal of Experimental Medicine 205 (11), pp.2457-2464. (10.1084/jem.20072378)
• Williams, A. S. et al. 2008. The role of death receptor 3 in inflammatory arthritis [Abstract]. Immunology 125 , pp.34-34. (10.1111/j.1365-2567.2008.02974.x)

2007

• Betts, G. et al., 2007. The impact of regulatory T cells on carcinogen-induced sarcogenesis. British Journal of Cancer 96 (12), pp.1849-1854. (10.1038/sj.bjc.6603824)